Beata Krzymieniewska
Overview
Explore the profile of Beata Krzymieniewska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Domka K, Dabkowska A, Janowska M, Urbanska Z, Pastorczak A, Winiarska M, et al.
Haematologica
. 2024 Jun;
109(11):3520-3532.
PMID: 38841802
Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL) is a high-risk subtype of acute lymphoblastic leukemia characterized by the presence of the BCR::ABL1 fusion gene. Tyrosine kinase inhibitors (TKI)...
2.
Szlendak U, Krzymieniewska B, Mendek-Czajkowska E, Rogatko-Koros M, Witkowska A, Wlodarska J, et al.
Cytokine
. 2021 Dec;
150:155780.
PMID: 34896730
Objective: Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal non-malignant disease in which hematopoietic cell apoptosis may play an important pathophysiological role. Previous studies of the content of phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3)...
3.
Krzywdzinska A, Pula B, Czyz A, Krzymieniewska B, Kiernicka-Parulska J, Mierzwa A, et al.
Diagnostics (Basel)
. 2021 Oct;
11(10).
PMID: 34679569
Minimal residual disease (MRD) status is now considered as one of the most relevant prognostic factors in multiple myeloma (MM) while MRD negativity became an important endpoint in clinical trials....
4.
Polak A, Bialopiotrowicz E, Krzymieniewska B, Wozniak J, Stojak M, Cybulska M, et al.
Cell Death Dis
. 2020 Nov;
11(11):956.
PMID: 33159047
Spleen tyrosine kinase (SYK) is an important oncogene and signaling mediator activated by cell surface receptors crucial for acute myeloid leukemia (AML) maintenance and progression. Genetic or pharmacologic inhibition of...